NCBI PubMed Central
open access
CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020#195820
- Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article#195822
- Identification of exhausted CD8(+) T-cell signatures for prognosis in multiple myeloma by integrated analysis of single-cell and bulk RNA-sequencing.#368076
- Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy.#222958
- Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma#1030467
Record · ID 662758
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive